Kronik Migrenli Hastalarda Bir Kliniğin Botulinum toksin A Deneyimi

Abstract

Abstract: Objective : The Botulinum toxin A (BoNT/A), increasingly used in many fields in recent years, was shown to be effective in chronic migraine (CM) in recent studies. In this study, we aimed to investigate treatment response in our CM patients who underwent BoNT/A therapy. Methods: The study included 41 CM patients (aged 18-65 years). We questioned patients undergoing BoNT/A therapy regarding demographic characteristics, education level, time of diagnosis, migraine triggers, and previous therapies at first visit prior to injection. The patients were assessed together with analgesic use, visual analog scale (VAS) score and Migraine Disability Assessment Score (MIDAS) rating at month 6 after treatment. Results: There were 36 women (87.8%) and 5 men (12.2%) in the study group. Mean age was calculated as 44.88±10.51 years. Of the patients, 20 patients (48.8%) fulfilled criteria for migraine with aura while no aura was detected in 21 patients (51.2%). Significant decrease was detected in MIDAS rating and VAS scores after BoNT/A therapy (p<0.001). Conclusion: The BoNT/A was found to be effective and safe in the prophylactic treatment of chronic migraine. The BoNT/A is a potent treatment that could be performed by experienced neurologists in eligible CM patients regardless of previous prophylactic treatments.